NCT02158780

Brief Summary

Undescended Testis is the most common congenital abnormality of the genitalia in boys and it is commonly managed by surgical intervention. Evidence in the medical literature to support the superiority of either scrotal or inguinal (standard) orchidopexy is lacking. To determine which technique is superior, this study focuses on the degree of post-operative pain after surgery. Therefore, the objective of this randomized control trial is to determine if scrotal orchidopexy reduces postoperative pain in children diagnosed with undescended testis when compared to standard inguinal orchidopexy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
162

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2014

Completed
20 days until next milestone

First Posted

Study publicly available on registry

June 9, 2014

Completed
7 months until next milestone

Study Start

First participant enrolled

January 1, 2015

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 22, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 22, 2021

Completed
Last Updated

February 25, 2021

Status Verified

August 1, 2019

Enrollment Period

6.1 years

First QC Date

May 20, 2014

Last Update Submit

February 23, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Analgesic use post-operatively (during hospital stay)

    Defined as the number of doses of morphine (standardized dose of 0.2 mg/kg) or Tylenol (15mg/kg) or Ibuprofen (10mg/kg) administered by PACU and SDSU nurses following surgery.

    Measured dosage post-surgery (on average 45 minutes later)

  • Analgesic use post-discharge

    Defined as number of standardized doses of Tylenol (15 mg/kg) and Ibuprofen (10 mg/kg) administered by parent/guardian at home post-discharge.

    Measure at 6 hour intervals post discharge for 48 hours

Secondary Outcomes (9)

  • Pain Scales post-operative (during hospital stay)

    Measure at patient admission and discharge at 30 minute intervals.

  • Pain Scales post-operative (during hospital stay)

    Measure at patient admission and discharge at 30 minute intervals.

  • Pain scales post-discharge

    Measure at 6 hour intervals post discharge for 48 hours

  • Analgesic use

    Measured dosage at the beginning of surgery and post-surgery (on average 45minutes later)

  • Duration of surgery (min)

    Record duration of operative time (takes on average 30-45 minutes)

  • +4 more secondary outcomes

Study Arms (2)

Scrotal Orchidopexy

EXPERIMENTAL

Single incision

Procedure: Scrotal Orchidopexy

Inguinal Orchidopexy

OTHER

Double Incision (Standard)

Procedure: Inguinal Orchidopexy

Interventions

Single incision

Scrotal Orchidopexy

Double Incision (Standard)

Inguinal Orchidopexy

Eligibility Criteria

Age10 Months - 7 Years
Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Diagnosis with palpable undescended testis (or testes);
  • Child is between 10 mos - 7 years of age;
  • Child requires either scrotal or inguinal orchidopexy

You may not qualify if:

  • Laparoscopic surgery for intra-abdominal testis or peeping testis (carnalicular);
  • Child underwent previous orchidopexy surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

McMaster Children Hospital

Hamilton, Ontario, L8N 3Z5, Canada

Location

Study Officials

  • Luis Braga, MD

    McMaster University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 20, 2014

First Posted

June 9, 2014

Study Start

January 1, 2015

Primary Completion

February 22, 2021

Study Completion

February 22, 2021

Last Updated

February 25, 2021

Record last verified: 2019-08

Locations